Lab
Medstar Laboratory, INC
Medstar Laboratory, INC was paid $37.33M by Medicaid between Jan 2018 and Dec 2024, across 163 billing codes. Its largest line is 84443, Thyroid stimulating hormone (TSH) — 7.3% of everything it billed.
33Billing provider infoMEDSTAR LABORATORY, INC
HILLSIDE, IL 60162
HILLSIDE, IL 60162
33aNPI1144202003assigned 11/16/2005
33bProvider typeClinical Medical Laboratory
28Total paid$37.33M
24GClaims3,557,236
24DCodes billed163
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Illinois
Rank by total paid#5 of 235
Median peer was paid$123K
This provider vs. median304×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 446,712 | $3.85M | |
| 2019 | 513,238 | $4.91M | |
| 2020 | 565,106 | $5.03M | |
| 2021 | 529,685 | $5.36M | |
| 2022 | 557,488 | $7.03M | |
| 2023 | 504,371 | $5.67M | |
| 2024incomplete | 440,636 | $5.47M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 84443 | Thyroid stimulating hormone (TSH) | 7.3% | 193,937 | 170,325 | $2.72M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 7.1% | 69,403 | 59,793 | $2.65M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 7.0% | 68,335 | 60,061 | $2.60M |
| 80074 | 5.4% | 60,911 | 52,985 | $2.01M | |
| 80053 | Comprehensive metabolic panel | 5.3% | 231,682 | 203,132 | $1.98M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 4.5% | 24,037 | 12,752 | $1.67M |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 3.9% | 59,108 | 51,504 | $1.46M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.5% | 259,453 | 228,894 | $1.29M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.2% | 29,084 | 24,192 | $1.21M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.1% | 120,928 | 107,252 | $1.14M |
| 80061 | Lipid panel | 2.8% | 227,455 | 199,659 | $1.06M |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.4% | 160,092 | 141,166 | $882K |
151 more codes
| 82607 | 2.0% | 75,126 | $760K | |
| 86704 | 1.8% | 51,610 | $690K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.7% | 29,463 | $625K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.7% | 72,750 | $621K |
| 86706 | 1.7% | 52,191 | $621K | |
| 84436 | 1.6% | 100,304 | $581K | |
| 86703 | 1.5% | 33,665 | $548K | |
| 82746 | 1.4% | 54,279 | $528K | |
| 84479 | 1.4% | 94,573 | $520K | |
| 86708 | 1.2% | 51,688 | $442K | |
| 86677 | 1.2% | 32,905 | $438K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.2% | 8,924 | $431K |
| 83735 | 1.2% | 75,016 | $430K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.1% | 18,036 | $410K |
| 81001 | 1.1% | 159,543 | $394K | |
| 86769 | <1% | 7,781 | $366K | |
| 82533 | <1% | 30,588 | $360K | |
| 81513 | <1% | 3,937 | $349K | |
| 85651 | <1% | 84,696 | $335K | |
| 87186 | <1% | 33,053 | $328K | |
| 83550 | <1% | 43,345 | $320K | |
| 82728 | <1% | 47,656 | $310K | |
| 83540 | <1% | 52,931 | $290K | |
| 84439 | <1% | 38,522 | $276K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 8,771 | $273K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 7,316 | $267K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 6,050 | $242K |
| 84153 | <1% | 20,675 | $230K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,702 | $219K |
| 87481 | <1% | 4,428 | $186K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 1,871 | $183K |
| 82150 | <1% | 31,026 | $181K | |
| 83695 | <1% | 23,639 | $178K | |
| 86592 | <1% | 49,289 | $176K | |
| 82570 | <1% | 36,086 | $146K | |
| 83655 | <1% | 13,833 | $145K | |
| 86038 | <1% | 10,901 | $139K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,075 | $139K |
| 82043 | <1% | 36,491 | $130K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 5,115 | $129K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,107 | $125K |
| 87563 | <1% | 5,446 | $119K | |
| 80050 | General health panel | <1% | 10,490 | $107K |
| 82977 | <1% | 32,708 | $104K | |
| 84550 | <1% | 32,850 | $102K | |
| 83615 | <1% | 27,600 | $99K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,876 | $99K |
| 84481 | <1% | 9,930 | $91K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 5,803 | $91K |
| 84480 | <1% | 10,518 | $82K | |
| 83001 | <1% | 5,025 | $81K | |
| 84100 | <1% | 26,265 | $77K | |
| 84703 | <1% | 12,186 | $77K | |
| 82550 | <1% | 17,466 | $77K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 129,139 | $71K |
| 86140 | <1% | 18,478 | $71K | |
| 87653 | <1% | 1,666 | $64K | |
| 86141 | <1% | 4,557 | $59K | |
| 84403 | <1% | 3,064 | $55K | |
| 86480 | <1% | 1,186 | $54K | |
| 84702 | <1% | 6,597 | $51K | |
| 86003 | <1% | 1,533 | $51K | |
| 84146 | <1% | 4,233 | $51K | |
| 87634 | <1% | 1,038 | $49K | |
| 86430 | <1% | 9,080 | $49K | |
| 86696 | <1% | 2,612 | $46K | |
| 83002 | <1% | 4,500 | $38K | |
| 86762 | <1% | 4,782 | $36K | |
| 85660 | <1% | 8,719 | $36K | |
| 86063 | <1% | 5,536 | $35K | |
| 84402 | <1% | 2,168 | $35K | |
| 85027 | <1% | 7,942 | $34K | |
| 86695 | <1% | 2,670 | $34K | |
| 86803 | <1% | 2,524 | $30K | |
| 82248 | <1% | 12,055 | $29K | |
| 87650 | <1% | 1,174 | $27K | |
| 85610 | <1% | 8,287 | $27K | |
| 83690 | <1% | 4,151 | $24K | |
| 83090 | <1% | 1,822 | $22K | |
| 85730 | <1% | 4,496 | $22K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 609 | $19K |
| 87077 | <1% | 11,784 | $19K | |
| 81025 | <1% | 6,860 | $17K | |
| 86694 | <1% | 1,317 | $16K | |
| 87340 | <1% | 1,588 | $14K | |
| 86901 | <1% | 3,475 | $13K | |
| 80076 | <1% | 3,228 | $11K | |
| 86735 | <1% | 964 | $11K | |
| 83525 | <1% | 2,645 | $11K | |
| 86900 | <1% | 3,465 | $11K | |
| 82652 | <1% | 634 | $10K | |
| 87625 | <1% | 391 | $10K | |
| 82785 | <1% | 1,491 | $9K | |
| 86765 | <1% | 1,160 | $9K | |
| 86787 | <1% | 601 | $8K | |
| 87075 | <1% | 770 | $8K | |
| 82274 | <1% | 832 | $7K | |
| 87905 | <1% | 574 | $6K | |
| 82378 | <1% | 460 | $5K | |
| 87081 | <1% | 1,016 | $5K | |
| 87808 | <1% | 365 | $5K | |
| 85018 | <1% | 2,450 | $5K | |
| 85014 | <1% | 2,376 | $5K | |
| 82670 | <1% | 412 | $4K | |
| 87450 | <1% | 615 | $4K | |
| 82465 | <1% | 1,940 | $4K | |
| 87102 | <1% | 682 | $4K | |
| 83880 | <1% | 326 | $4K | |
| 87070 | <1% | 669 | $3K | |
| 87338 | <1% | 210 | $3K | |
| 87210 | <1% | 792 | $3K | |
| 80164 | <1% | 409 | $3K | |
| 83970 | <1% | 99 | $3K | |
| 86301 | <1% | 133 | $3K | |
| 80185 | <1% | 230 | $2K | |
| 86304 | <1% | 110 | $2K | |
| 84144 | <1% | 202 | $2K | |
| 85045 | <1% | 966 | $2K | |
| 86481 | <1% | 61 | $2K | |
| 84460 | <1% | 1,084 | $1K | |
| 86780 | <1% | 93 | $1K | |
| 84450 | <1% | 1,054 | $1K | |
| 83021 | <1% | 123 | $1K | |
| 82105 | <1% | 78 | $1K | |
| 99000 | <1% | 1,108 | $1K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 319 | $790.90 |
| 84432 | <1% | 60 | $788.57 | |
| 86235 | <1% | 59 | $660.61 | |
| 84156 | <1% | 389 | $641.63 | |
| 82950 | <1% | 146 | $632.12 | |
| 83721 | <1% | 587 | $626.16 | |
| 87522 | Neg quan hep c or qual rna | <1% | 12 | $507.63 |
| 84154 | <1% | 52 | $490.81 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 54 | $483.55 |
| 86593 | <1% | 131 | $456.81 | |
| 82565 | <1% | 780 | $396.66 | |
| 86800 | <1% | 32 | $355.98 | |
| 86376 | <1% | 55 | $345.68 | |
| 82947 | <1% | 146 | $326.17 | |
| 84075 | <1% | 745 | $315.19 | |
| 83020 | <1% | 12 | $263.72 | |
| 84520 | <1% | 752 | $262.59 | |
| 82677 | <1% | 30 | $261.97 | |
| 80177 | <1% | 30 | $229.48 | |
| 86336 | <1% | 13 | $226.04 | |
| 86200 | <1% | 27 | $221.39 | |
| 86705 | <1% | 20 | $212.28 | |
| 82040 | <1% | 712 | $158.27 | |
| 84132 | <1% | 35 | $137.71 | |
| 82679 | <1% | 13 | $120.45 | |
| 86709 | <1% | 20 | $76.57 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPATEL, RAJ (VICE PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Sea of Smiles | Yardley, PA | $183K |
| Pediatric Dental Health, LLC | Bensalem, PA | $91K |
| Sea of Smiles 3PLLC | Warrington, PA | $53K |
| Sea of Smiles 4 LLC | Jenkintown, PA | $23K |
| True Dermatology, LLC | Alabaster, AL | $915.60 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.